Our Youtube Channel Has Longer Presentations On These Subjects:
- Extending the Quality of Your Life, 2) Coronary Artery Disease, 3) Stroke, 4) Parkinsons Disease, 5) Peripheral Artery Disease, 6) Diabetic Foot Ulcers, 7) Multiple Sclerosis, 8) Depression, 9) ALS/Motor Neuron Disease, and 10) Alzheimers Disease.
We believe this vision into the future of regenerative medicine is a medical breakthrough which will affect all of us. We look forward to seeing you at this highly informative presentation.
Zhittya Gets Regulatory Approval In Mexico For Trial Of Drug In Pd Patients
Zhittya Genesis Medicine has secured regulatory approval from Mexico’s governing body COFEPRIS to test its drug in people with Parkinson’s disease .
Zhittya Genesis Medicine has secured regulatory approval from Mexicos governing body COFEPRIS to test its drug in people with Parkinsons disease .
The first phase of the clinical trial will be held at the Zambrano Hospital in Monterrey, Mexico.
Through preclinical studies, the drug earlier indicated its ability to halt and even reverse the decline in motor symptoms in patients.
The trial will see three ascending doses of the drug being tested in subjects with mild to moderately severe Parkinsons disease.
There will be no placebo dose administered in this first-in-man proof-of-concept study.
Zhittyas drug has indicated the ability to arrest the decline and boost the motor skills of the animals tested in preclinical studies on rodents and primates.
Regeneration of newly formed dopamine-producing neurons was also seen in the treated animals, indicating that the drug seems to be impacting the root cause of Parkinsons disease, the loss of these specialised neurons.
Although the primary aim of this trial is to test for the safety of the drug, it will also study any improvements in the patients Parkinson disease symptoms.
The firm also plans to file applications to test its drug in patients with chronic stroke and major depressive disorder.
Related Companies
Fibroblast Growth Factor 1
Alternative Names:
Latest Information Update: 11 Aug 2022
- Adis is an information provider.We do not sell or distribute actual drugs.
- Final gross price and currency may vary according to local VAT and billing address.
- Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
- A link to download a PDF version of the drug profile will be included in your email receipt.
Also Check: Can Essential Tremors Lead To Parkinson’s
Why Should You Join Us For This Live Webinar
- Learn that there is hope to treat these devastating diseases over the next few years.
- Understand why Therapeutic Angiogenesis could be the biggest breakthrough in medicine in this century.
- Understand that lack of blood flow is the cause of many diseases throughout the body and treating this lack of blood flow will improve your quality of life as you age.
- Learn that as we age, less blood flow in our brains can lead to cognitive decline and may initiate Alzheimers disease.
- Hear about research that indicates vascular dysfunction may be causative factors in Parkinsons disease, Alzheimers disease, and multiple sclerosis.
- See dramatic results in a monkey model of Parkinsons disease where Therapeutic Angiogenesis reversed this disease by regenerating new dopamine neurons and alleviating the debilitating motor symptoms of this neurodegenerative disease.
To register for the web presentation, go to:
For more information, please visit Zhittyas website: zgm.care
Please check out our YouTube channel:
Compassionate Use Clinical Trial Of Fgf
Zhittya Genesis Medicine announced the trial to evaluate its biological drug, FGF-1, which is administered via an intranasal delivery device, in a cohort of individuals with mild to moderate ALS.
Zhittya Genesis Medicine recently announced the initiation of a Compassionate Use Clinical Trial for the treatment of amyotrophic lateral sclerosis . The trial will evaluate the companys proprietary FGF-1 biological drug with an intranasal delivery device to introduce medicine into the brain.1
The human proof-of-concept study will enroll patients with mild to moderately severe ALS and aim to establish safety of the treatment, as well as possible improvements in symptoms of the disease. There will be no placebo dose administered.
Starting this Compassionate Use Clinical Trial represents another major step for us and our partners in learning whether our medicine is safe in humans and, if so, whether we can modify the progression of ALS to enhance outcomes for those afflicted by this terrible disease, Daniel C. Montano, CEO, Zhittya, said in a statement.1 Over the last 2 decades, weve dedicated tremendous resources to reach the point where we can now officially test our hypothesis that ALS is a disorder caused by issues of micro-vascularization within the brain. We are entering a true proof of concept trial that will hopefully indicate we can treat and possibly evenreversethe effects of ALS.
You May Like: Can Cancer Cause Parkinson’s
P Biopharmaceuticals A Leading Contract Development And Manufacturing Organization Specialized In Process Development And Cgmp Manufacturing Of Biologics And The American Biotech Company Zhittya Genesis Medicine Have Successfully Accomplished A Tech Transfer
3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies.
After successfully achieving the transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
The candidate protein selected by Zhittya is human FGF-1, which is a growth factor involved in stimulating new blood vessel growth and new neuron growth . These properties make FGF-1 an excellent therapeutic candidate for treating neurodegenerative diseases, such as Parkinsons disease, Zhittyas lead drug development program. Phase I clinical trials are being planned for this indication in the US, Mexico and Europe.
Recent research from several medical centers has indicated that a number of neurodegenerative diseases, including Parkinsons disease, Alzheimers disease and amyotrophic lateral sclerosis , are initiated by vascular dysfunction in the brain leading to defective blood perfusion and loss of neurons in selected regions of the brain.
This partnership once again demonstrates the knowledge and capacity of 3P to carry out process development and manufacturing that is adapted to the needs of each client using mammalian and/or microbial systems. Furthermore, this collaboration supports 3P´s strategic goal to further expand its presence in the US market.
Parkinson’s Disease: Midland Texasdate: Wednesday October 12 2022location: Petroleum Club Of Midland Texas
Join Zhittya and two Parkinson’s Disease study participants in a presentation about Zhittya’s novel approach of using Zhittya’s FGF-1 to revascularize the brains of individuals with Parkinson’s Disease in an attempt to reestablish blood flow to the dopmaine producing regions of the brain and relive the symptoms of Parkinson’s Disease
With positive animal data in both mice and monkeys, Zhittya’s newest endeavour into treating humans in a medical research study is showing hints of improvement! Hear from Zhittya and two study participants in this presentation!
Zhittya believes that FGF-1, a potent growth factor and stimulator of angiogenesis could be a possible treatment for Parkinson’s Disease. One of our research subjects’ right hand experienced severe tremors and following dosage of FGF-1 over a two week period was able to hold a beer bottle in his right hand without tremors. Examples such as this, and many more give Zhittya hope that FGF-1 could be a possible treatment for Parkinson’s Disease.
Don’t Miss: What Is The Best Exercise For Parkinson’s
Zhittya Genesis Medicine Announces A Potential Major Medical Breakthrough For The Treatment Of Parkinsons Diseaseparkinsons Disease: Is Therapeutic Angiogenesis A Treatment Or Even A Possible Cure
LAS VEGAS, Sept. 22, 2020 — Zhittya Genesis Medicine, Inc. , a private company, announces that it will initiate clinical trials to test a medical hypothesis that has been advanced over the last five years that Parkinsons disease may be caused by vascular disruption in the areas of the brain which house the dopamine-producing neurons, those neurons which become dysfunctional in patients suffering from this disorder. The hypothesis is simply that the micro-vascularization in that area of the brain is blocked or narrowed, restricting the flow of blood needed to nourish these neurons, resulting in the classical symptoms of Parkinsons disease, including tremor and gait disturbances. Just as in the heart, blockage of coronary arteries can lead to angina and heart attacks, that same process is now thought to underlie the development of Parkinsons disease.
Zhittya will give a Zoom Webinar on its potential breakthrough therapy to reverse the progression of Parkinsons disease on Tuesday September 29, 2020 at 8:00 AM Pacific time . The webinar is available to all interested parties, free of charge. Currently, no therapies on the market can halt or reverse Parkinsons disease. Zhittya is advancing upon what it believes could be a disease modifying agent that has the potential to slow down and possibly even reverse the inexorable decline seen in patients who suffer from this devastating disease.
To register for this webinar go to: zgm-parkinsons.com
Contact information:
Is Angiogenesis A Treatment And Potential Cure
Zhittya Genesis Medicine is developing a drug, fibroblast growth factor 1 , to possibly treat Parkinson’s disease by growing new blood vessels in the brains of individuals suffering from Parkinson’s. FGF-1 is a potent stimulator of angiogenesis and is capable of growing these new blood vessels in ischemic areas of the body, including the brain. Research has indicated that a lack of blood perfusion to dopamine producing neurons located in the substantia nigra region of the brain lead to a lack of dopamine and the classic symptoms of Parkinson’s.
In the past, FGF-1 has been able to grow new blood vessels in the human body. In a US FDA Phase IIA clinical trial, conducted at the University of Cincinnati, our drug was able to grow new blood vessels in the hearts of individuals with coronary artery disease, improving many of their symptoms.
FGF-1 has also shown excellent efficacy in treating Parkinson’s disease in Cynomolgus monkey models. After being injected with a neurotoxin that selectively destroys dopamine-producing neurons, the two groups of monkeys came down with the classic symptoms of Parkinson’s disease. After one group was administered FGF-1 and the other a placebo dose, the FGF-1 administered monkeys not only improved their motor scores almost to normal, but also increased their dopamine production and decreased their build up of alpha-synuclein plaque.
Also Check: Does Exercise Help Parkinson’s Disease
Zhittya Genesis Medicine Starts Parkinson’s Disease Clinical Trial
LAS VEGAS, Jan. 12, 2022 — Zhittya Genesis Medicine, Inc. , announced that it is starting a Compassionate Use Clinical Trial for treatment of Parkinsons disease. Zhittyas Compassionate Use Clinical Trial will utilize Zhittyas proprietary FGF-1 biological drug in conjunction with a proprietary intranasal device to introduce its medicine into the brain via the nasal cavity.
Zhittya is currently advancing what it believes could be a disease modifying agent, as its drug has previously demonstrated, through preclinical studies, the ability to potentially halt and even reverse the inexorable decline in motor symptoms seen in patients with Parkinsons disease.
Over the last five years, a new medical hypothesis has been proposed that Parkinsons disease may be initiated by vascular disruption in the areas of the brain which house dopamine-producing neurons. The theory holds that, over time, micro-vascularization in the brain becomes blocked, narrowed or leaky, leading to blood flow restriction, which prevents the affected neurons from receiving proper nourishment. This disruption of a natural biological process can lead to the classical symptoms of Parkinsons disease, including tremor and gait disturbances.
Zhittya Contact:
Zhittya Genesis Medicine Announces: Free Zoom Webinar: Parkinsons Disease Sufferers Motor Skills Improve By 50% After Medical Research Study
LAS VEGAS, June 21, 2022 — Zhittya Genesis Medicine, Inc. , announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time presenting evidence and analysis of improvements in Parkinsons Disease sufferers in Zhittyas Medical Research Study. To register for this webinar and see the visual and analytical improvements in the motor functions of Parkinsons Disease sufferers visit zgm.care.
Analysis of motor scores indicates that the human test subjects had a 50% improvement in their motor skills. Zhittyas study utilized their human FGF-1 biological drug candidate in conjunction with a proprietary intranasal delivery device to introduce its medicine into the brain. The patients received two escalating doses of intranasally-delivered FGF-1 and were monitored for adverse events. Thusfar, no adverse events have been seen in the subjects during the medical research study nor following the conclusion of the dosing regime. Analysis of videos, patient surveys, and observations from the principal investigator show promising signs of motor and cognitive improvement.
Again, Zhittyas free Zoom webinar on the first-in-human results from our FGF-1 intranasal delivery study in Parkinsons disease subjects will air on June 23, 2022, at 3 pm Pacific time To register for the webinar, go to: zgm.care
Zhittya Contact:
You May Like: How Does Parkinson’s Start
Is Therapeutic Angiogenesis A Revolutionary Medical Breakthrough To Treat These Diseases
Live Presentation Wednesday, March 24, 2021
8:00 pm, Dubai Time
Head of Cardiovascular Department, Kings College Hospital London, in Dubai.
Jack Jacobs, PhD
President and Chief Scientific Officer
Zhittya Genesis Medicine, Inc.
Zhittya Genesis Medicine, Inc. is a U.S. based biotech company developing novel pharmaceuticals that have the potential to treat and possibly reverse diseases that account for more than 50% of all adult deaths and suffering worldwide. In US FDA-authorized clinical trials, those drugs have shown remarkable success in reversing severe coronary artery disease and healing diabetic foot ulcers. New clinical trials are planned this year to treat patients with Parkinsons disease, ALS , peripheral artery disease, multiple sclerosis, chronic stroke, and Alzheimers disease.
Dr. Omar Hallak, Head of Cardiovascular Department at Kings College Hospital London, in Dubai, wishes to make you aware of these potential breakthrough medicines that stimulate Therapeutic Angiogenesis and are now advancing through the clinical and regulatory approval processes. These new medical treatments may change the course of disease and suffering for 50% of the people in the world.
Zhittya Genesis Medicine Announces: Parkinsons Disease Sufferers Motor Skills Improved By 50% After Medical Research Study
First-In-Human Study of FGF-1 Delivered Into the Brain Via a Novel Intranasal Treatment for Parkinsons Disease
LAS VEGAS, June 16, 2022 — Zhittya Genesis Medicine, Inc. , announced that the human test subjects in its first-in-human research study for the treatment of Parkinsons disease, at the 30 interim examination had a 50% improvement in their motor skills. Zhittyas study utilized their human FGF-1 biological drug candidate in conjunction with a proprietary intranasal delivery device to introduce its medicine into the brain. Previous preclinical work established that twice the amount of FGF-1 could be delivered into the brain via the intranasal route versus the intravenous route. Intranasal dosing started on human test subjects on May 3, 2022 and concluded on May 30, 2022 with the patients receiving two escalating doses of intranasal FGF-1. No adverse events to date have been seen in the subjects and analysis of videos taken before and after treatment showed promising signs of motor skill improvement, according to the test subjects and the Principal Investigator supervising the trial. Additional follow-up sessions will occur at 60-days and 90-days post-treatment to assess any adverse events that may have appeared and to document any continued progress towards reversing the test subjects’ Parkinson’s disease.
Zhittya Contact:
Read Also: Can Parkinson’s Cause Weight Loss
About Zhittya Genesis Medicine Inc
Who We Are
Zhittya is a biotechnology company based in Las Vegas, Nevada. We are seeking to commercialize human FGF-1, a potent, naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Since 1998, Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs have been working to bring this drug to market. Zhittya’s management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. In fact, there are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues, and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.
A New Era For Parkinsons Disease Treatment
March 2, 2022 | By
A non-invasive ultrasound treatment for Parkinsons disease that was tested in a pivotal trial led by University of Maryland School of Medicine researchers is now broadly available at the University of Maryland Medical Center .
Howard Eisenberg, MD, Dheeraj Gandhi, MD, MBBS, Paul Fishman, MD, PhD, Bert W. OMalley, MD.
The device, called Exablate Neuro, was approved in November by the U.S. Food and Drug Administration to treat advanced Parkinsons disease on one side of the brain. The approval was based on findings from the UMSOM clinical trial and effectively expands access to focused ultrasound beyond clinical trial participation.
Rapid Reversal of Symptoms
Focused ultrasound is an incisionless procedure, performed without the need for anesthesia or an in-patient stay in the hospital. Patients, who are fully alert, lie in a magnetic resonance imaging scanner, wearing a transducer helmet. Ultrasonic energy is targeted through the skull to the globus pallidus, a structure deep in the brain that helps control regular voluntary movement. MRI images provide doctors with a real-time temperature map of the area being treated. During the procedure, the patient is awake and providing feedback, which allows doctors to monitor the immediate effects of the tissue ablation and make adjustments as needed.
Patient: Focused Ultrasound Changed My Life
A New Era for Parkinsons Disease Treatment
Recommended Reading: Tango For Parkinson’s Disease
Zhittya Genesis Medicine Starts Parkinsons Disease Clinical Trial
LAS VEGAS, Jan. 12, 2022 — Zhittya Genesis Medicine, Inc. , announced that it is starting a Compassionate Use Clinical Trial for treatment of Parkinsons disease. Zhittyas Compassionate Use Clinical Trial will utilize Zhittyas proprietary FGF-1 biological drug in conjunction with a proprietary intranasal device to introduce its medicine into the brain via the nasal cavity.
Zhittya is currently advancing what it believes could be a disease modifying agent, as its drug has previously demonstrated, through preclinical studies, the ability to potentially halt and even reverse the inexorable decline in motor symptoms seen in patients with Parkinsons disease.
Over the last five years, a new medical hypothesis has been proposed that Parkinsons disease may be initiated by vascular disruption in the areas of the brain which house dopamine-producing neurons. The theory holds that, over time, micro-vascularization in the brain becomes blocked, narrowed or leaky, leading to blood flow restriction, which prevents the affected neurons from receiving proper nourishment. This disruption of a natural biological process can lead to the classical symptoms of Parkinsons disease, including tremor and gait disturbances.
Trump legal team balks at judge’s declassification questions
Zhittya Contact: